A Multicenter,Randomized Controlled Clinical Study on Ceftriaxone/Sulbactam and Cefoperazone/Sulbact

来源 :第四届国际人体微生态大会、第十三届中华预防医学会微生态学学术会议、第五届中国医师协会感染科医师大会暨传染病诊治高峰论坛、 | 被引量 : 0次 | 上传用户:coldcoffee
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Background Ceftriaxone/sulbactam (4:1) is a novel β-lactam/β-lactamase-inhibitor combination injection.A clinical study was designed to evaluate its efficacy and safety in the treatment of respiratory and urinary infections caused by ceftriaxone-resistant bacteria comparing with cefoperazone/sulbactam (2:1) on cefoperazone-resistant bacteria.
其他文献
会议
会议
Taylors power law (Taylor 1961,Nature,189:732-735) has been found to govern the population abundance distributions of single species in macro-ecology,and here we test its applicability to the bacteria
会议
会议
会议
Objective To investigate the drug resistance of Escherichia coli in liver cirrhosis combined with spontaneous bacterial peritonitis (SBP),and provide the credible evidence with the clinic diagnosis an
会议
Background HIV-related opportunistic infections (OIs) and malignancies continued to cause morbidity and mortality in Chinese HIV-infected individuals.The objective for this study is to elucidate the p
会议
会议
Objective To study whether CO-Q10 can protect liver injury caused by acute on chronic liver failure(ACLF)by autophagy.Methods Rats were separated into three groups:control group,acute on chronic liver
会议
本文总结了3月以下婴儿无乳链球菌感染的临床表现、耐药性分析、抗生素治疗及预后的特点.研究发现使用万古霉素及利奈唑胺等抗生素并未增加益处;预后方面无乳链球菌脑膜炎的预后均较好,无死亡及严重后遗症病例。